Table 2.

Selected Phase III Trials of Platinum-Based Combination Chemotherapy Duration

Trial	Year	Treatment	No. of Patients	% of Patients Completing Treatment	Second-Line Therapy (% of patients)	PFS		OS
						Median	P	Median	P
Smith et al35	2001	MVP × 3 cycles	155	72	NR	5 months	.4	6 months	.2
		MVP × 6 cycles	153	31	NR	5 months		7 months
Socinski et al15	2002	CP × 4 cycles	114	57	42 (single-agent paclitaxel)	NR	—	6.6 months	.63
		CP until PD	116	—	47 (single-agent paclitaxel)	NR		8.5 months
von Plessen et al36	2006	Carboplatin AUC 5 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 every 21 days × 3 cycles	150	78	12	16 weeks	.21	28 weeks	.75
		Carboplatin AUC 5 on day 1 and vinorelbine 25 mg/m2 on days 1 and 8 every 21 days × 6 cycles	147	54	10	21 weeks		32 weeks
Park et al37	2007	Third-generation platinum doublet* × 4 cycles	156	92	74	4.6 months	.001	15.9 months	.46
		Third-generation platinum doublet* × 6 cycles	158	68	63	6.2 months		14.9 months
Barata et al38	2007	Carboplatin-gemcitabine × 4 cycles	110	Median No. of cycles = 3.5	14 (docetaxel)	4 months	.08	7 months	.05
		Carboplatin-gemcitabine × 6 cycles	110	Median No. of cycles = 4.8	15 (docetaxel)	5 months		12 months

Abbreviations: AUC, area under the curve; CP, carboplatin AUC 6 and paclitaxel 200 mg/m² every 21 days; MVP, mitomycin 8 mg/m² (courses 1, 2, 4, and 6), vinblastine 6 mg/m², and cisplatin 50 mg/m² every 21 days; NR, not reported; OS, overall survival; PD, progressive disease; PFS, progression-free survival.

^*Cisplatin 70 mg/m² on day 1 plus either paclitaxel 175 mg/m² on day 1 or docetaxel 75 mg/m² on day 1 or gemcitabine 1,000 mg/m² on days 1 and 8 every 21 days.